Pacific Biosciences of California (NASDAQ:PACB) Announces Quarterly Earnings Results

Pacific Biosciences of California (NASDAQ:PACB) posted its earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07, Zacks reports. The business had revenue of $44.65 million during the quarter, compared to the consensus estimate of $44.60 million. Pacific Biosciences of California had a negative return on equity of 101.49% and a negative net margin of 325.02%.

Here are the key takeaways from Pacific Biosciences of California’s conference call:

• Q4 revenue was $44.6M (+14% YoY) and full‑year 2025 revenue was $160M (+4%); management guided 2026 revenue of $165–$180M (midpoint ~$172M, ~8% growth) and expects further gross‑margin expansion.
• Consumables momentum drove non‑GAAP gross margin to 40%, with consumable shipments up ~19% YoY and a 55% increase to clinical/hospital customers, while Revio pull‑through was about $242K annualized and Q4 placements included 21 Revio and 42 Vega systems.
• The planned 2026 launch of SparkNex (multi‑use Smart Cells) showed encouraging beta results—~25% higher output and a target cost below $300 per HiFi genome—which management says should lower customer per‑sample costs, expand addressable market, and improve margins.
• PacBio remains loss‑making (non‑GAAP net loss $158.8M in 2025) with ~$280M cash after a ~$48M short‑read asset sale; key risks include a muted academic funding environment weighing on instrument demand and component/compute (memory) cost volatility that could pressure margins.

Pacific Biosciences of California Stock Down 2.3%

PACB traded down $0.04 on Friday, reaching $1.80. The company’s stock had a trading volume of 1,726,899 shares, compared to its average volume of 7,967,145. The business’s 50 day moving average is $2.09 and its 200 day moving average is $1.77. The stock has a market cap of $542.53 million, a price-to-earnings ratio of -0.82 and a beta of 2.27. Pacific Biosciences of California has a 1 year low of $0.85 and a 1 year high of $2.73. The company has a debt-to-equity ratio of 17.88, a current ratio of 6.24 and a quick ratio of 5.40.

Institutional Investors Weigh In On Pacific Biosciences of California

Several large investors have recently added to or reduced their stakes in the stock. Zacks Investment Management acquired a new stake in Pacific Biosciences of California in the third quarter worth approximately $25,000. Russell Investments Group Ltd. acquired a new stake in shares of Pacific Biosciences of California during the 3rd quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd grew its position in Pacific Biosciences of California by 891.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 22,776 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 20,478 shares during the period. Cibc World Markets Corp acquired a new position in Pacific Biosciences of California during the 4th quarter worth about $34,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Pacific Biosciences of California during the 3rd quarter worth about $38,000.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PACB shares. Piper Sandler lifted their price objective on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Stephens upped their price objective on Pacific Biosciences of California from $1.80 to $2.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Finally, Barclays lifted their target price on Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pacific Biosciences of California presently has a consensus rating of “Hold” and a consensus target price of $2.08.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.